Special Issue "Nanomedicine in Drug Delivery"
Deadline for manuscript submissions: closed (31 July 2021).
Interests: nanomedicine; drug delivery; biomaterials; liposomes; lipoprotein mimetics; biophysical characterization; structural biology
Nanomedicine is an emerging field that fosters the development of novel concepts in drug delivery and the exploration of innovative treatment strategies to combat major diseases. Synthetically manufactured nanoparticles, biomimetic or bio-inspired nanocarriers, nanocomposites, and nanostructured materials with optimized properties are being considered as a new paradigm in the therapy of diseases. “Smart” nanocarriers are developed with high payload capacity to deliver new drugs, target specific cell types or tissues, cross physiological barriers to reach their target, improve the therapeutic window of drugs, and to reduce unwanted side effects. Nanomedicine-based treatment strategies include innovative pharmaceutical carriers for immunotherapy, gene therapy, or combination therapy with perspectives towards personalized medicine. However, to enable the translation from basic research to clinical applications and marketed nanopharmaceuticals, transdisciplinary approaches are needed.
The Special Issue aims to present novel nanomedicine-inspired delivery systems, including ligand-targeted nanoparticles for site-specific transport of pharmaceuticals, improved production and characterization techniques for pharmaceutical nanoparticles, and exploration of alternative routes of administration and delivery strategies. Topics may also include any aspects of functional nanomaterials in therapy. State-of-the-art research on promising nanomedicine-based drug delivery systems with perspectives for clinical translation are welcome.
Prof. Dr. Ruth Prassl
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- nanoparticles, nanocomposites, nanostructured materials, and biomimetics for drug delivery
- innovative nanoparticles for immunotherapy, gene therapy, or combination therapy
- ligand-targeted nanocarriers
- new nanoparticle production and characterization techniques
- alternative administration routes and delivery strategies for nanopharmaceuticals
- clinical translation